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The nucleotide sequence of cDNA encoding the human substance P precursor, /?-preprotachykinin @-PPT), 
has been determined. The source of mRNA was a human laryngeal carcinoid tumour that contained a high 
concentration of immunoreactive substance P. The human b-PPT polypeptide is 129 amino acids long and 
contains regions encoding substance P and neurokinin A, each flanked by basic amino acid residues. Resi- 
dues 72- IO7 of the human p-PPT polypeptide encode the sequence of neuropeptide K, an N-terminally ex- 
tended form of neurokinin A recently isolated from porcine brain. 
Substance P Substance K Neuropeptide K Tachykinin mRNA Carcinoid tumour 
1. INTRODUCTION 
Substance P was, until recently, the only known 
representative in mammals of the tachykinins, a 
family of neuropeptides characterised by the com- 
mon C-terminal amino acid sequence -Phe-X-Gly- 
Leu-Met-NHz, where X is a hydrophobic or 
aromatic residue [l]. Three further mammalian 
tachykinins have now been described: NkA [2], 
neurokinin B and NpK [3], an N-terminally ex- 
tended form of NkA. In bovine brain, SP is de- 
rived from two closely related precursor poly- 
peptides (cu- and p-PPT [4]). In addition to a 
region encoding the sequence of SP, &PPT con- 
tains the sequences of NkA and NpK. SP and NkA 
are thought to exert their actions through separate 
classes of tachykinin receptors (‘SP-P’ and ‘SP-K’ 
receptors, respectively), which have different 
distributions in the nervous system [5]. 
Abbreviations: cDNA, complementary DNA; mRNA, 
messenger RNA; NkA, neurokinin A (formerly known 
as substance K, neuromedin L or neurokinin cu); NpK, 
neuropeptide K; PPT, preprotachykinin; SP, substance 
P 
We report here the nucleotide sequence of 
cDNA encoding human ,&PPT. Human carcinoid 
tumours have been shown to contain and secrete 
large amounts of tachykinin-immunoreactive pep- 
tides, including SP, NkA [6] and a peptide with 
chromatographic and immunochemical properties 
similar to those of NpK [7]. Accordingly, for the 
cDNA cloning, we have used as the source of 
mRNA a metastatic deposit from a laryngeal car- 
cinoid tumour which contained abundant (- 1 pg/g 
wet wt) SP-like immunoreactivity. The tumour 
caused hypersalivation and local pain in the pa- 
tient, possibly as a consequence of ectopic SP pro- 
duction [8]. Human ,&PPT cDNA shows extensive 
homology to bovine ,&PPT cDNA [2] and includes 
regions encoding the sequences of SP, NkA and 
NpK. 
2. EXPERIMENTAL 
2.1. cDNA synthesis and construction of 
recombinant plasmids 
Poly(A)+ RNA was isolated from 3.5 g tumour 
tissue using the guanidine thiocyanate procedure 
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[9] and chromatography on oligo(dT) cellulose 
[lo]. Double-stranded cDNA was synthesised us- 
ing either oligo(dT)i2-18 or the synthetic hep- 
tadecamer probe I as primer (fig. 1: supplied by 
Celltech). The procedures of Craig et al. [l l] were 
used for the first strand and those of Gubler and 
Hoffmann [12] for the second strand. Double- 
stranded cDNA was tailed with approx. 25 dC 
residues. using terminal deoxynucleotidyl 
transferase as described by the suppliers (Bethesda 
Research Laboratories). 
Poly(dC)-tailed cDNA and poly(dG)-tailed, 
Pstl-restricted pBR322 DNA (New England 
Nuclear) were annealed [ 131 at final concentrations 
of 8 and 400 ng/ml, respectively. The resulting 
chimeric plasmids were then used to transform E. 
coli RR1 [14]. Aliquots of the transformed cells 
were plated onto L-agar containing lOpg/ml 
tetracycline and incubated overnight at 37°C. 
Tetracycline-resistant colonies were then picked in 
triplicate onto Biodyne filters overlaying agar and 
allowed to grow overnight at 37°C prior to storage 
or colony filter hybridisation. 
2.2. Colony screening 
To identify clones containing PPT sequences, 
filters were grown overnight on L-agar plates con- 
taining tetracycline (10 pg/ml) and chloram- 
phenicol (250rg/ml) prior to screening with 
synthetic 17-mer probes (fig. 1). Bacteria were lysed 
and the DNA was fixed onto the filters as de- 
scribed by Grunstein and Hogness [15]. Filters 
were prehybridised for 18 h at 37°C in a solution 
containing 0.9 M NaCI, 60 mM EDTA, 19.8 mM 
Tris-HCI (pH 8) and 0.1% each of bovine serum 
albumin, polyvinyl pyrrolidone and Ficoll (5 x 
Denhardt’s reagent) then hybridised in an identical 
solution containing hybridisation probe, labelled 
at the 5 ‘-end with [Y-~~P]ATP [16]. Filters were 
hybridised for 18 h at 37°C and were then washed 
five times (30 min per wash) with 0.9 M NaCl, 
0.09 M sodium citrate, pH 7 (6 x SSC), at room 
temperature and twice with 6 x SSC/O. 1% SDS at 
35°C. Filters were dried and exposed to Kodak X- 
Omat S film for 24-72 h using Kodak X-Omatic 
intensifying screens. 
2.3. Nucleotide sequence determination 
The sequences of portions of 2 clones containing 
,&PPT cDNA (phE293 and ph8.216) were deter- 
68 
mined by the method of Sanger et al. [17] after 
subcloning of suitable restriction fragments into 
bacteriophages Ml3 mp18 or Ml3 mp19. 
2.4. Northern blot analysis of human ,6 -PPT 
mRNA 
Polyadenylated RNA (1 bug) isolated from the 
tumour was fractionated by electrophoresis on a 
formaldehyde-containing 1% (w/v) agarose gel 
and the RNA blotted onto a nylon membrane [18]. 
The membrane was hybridised with 32P-labelled, 
nick-translated plasmid phE293 and washed as 
described [ 181. 
3. RESULTS 
3.1. Identification and sequence of p-PPT cDNA 
A cDNA library of 8700 transformants was 
generated from total poly(A)+ RNA using cDNA 
synthesised with oligo(dT)i2_i8 as the primer. 
Identification of one cDNA clone (phE293) en- 
coding PPT was achieved by screening duplicate 
filters of the library with 32P-labelled probe I, 
which is complementary to both the SP and NkA 
coding regions of bovine,&PPT. Sequencing of the 
cDNA insert in phE293 revealed that it consisted 
of 904 bp. The insert included an open reading 
frame which encoded a PPT, extending for 321 bp 
from the 5’-end, followed by 553 bp of 
3 ‘-untranslated region and 30 nucleotides of 
poly(A)+ tail. 
The 5 ‘-end of the insert in phE293 interrupted 
the open reading frame coding for PPT, indicating 
that reverse transcription had not proceeded to the 
5 ’ -end of the mRNA and that phE293 did not con- 
tain the entire fl-PPT cDNA. In addition, Nor- 
thern blot analysis demonstrated that the smallest 
and most abundant PPT mRNA in human tissue 
consisted of approx. 1200 nucleotides, some 300 
nucleotides larger than the insert in phE293 (fig.2). 
Therefore an additional cDNA library was con- 
structed from the tumour poly(A)+ RNA to obtain 
the region corresponding to the 5’-end of the PPT 
mRNA. To enrich for the desired clones, cDNA 
was synthesised using probe I as a PPT-specific 
primer. A second 17-mer (probe II, fig.1; supplied 
by Dr S. Minter, UMIST) complementary to a 
region close to the 5 ‘-end of the insert in phE293 
was used to screen 2700 recombinants; one clone 
(ph8.216) gave a strong hybridisation signal. The 
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5 ’ -TTTGCCCAT;A;TCCAA-3 ’ PROBE I 4. DISCUSSION 
5’-GTCGTACCAGTCGGACC-3 ’ PROBE II 
Fig.1. Sequences of oligonucleotides used for screening 
of human cDNA libraries and as primers for cDNA 
synthesis. Probe I is complementary to parts of the SP- 
and NkA-coding regions of bovine @-PPT cDNA 
(nucleotides 337-353 and 454-470 of the published 
sequence [4]). Probe II is complementary to a region of 
human ,&PPT cDNA close to the 5 ‘-end of the insert in 
phE293 (nucleotides 173-189 in fig.3). 
4800 
3800 
2700 
1900 
1200 
Fig.2. Northern blot analysis of 1 pug of polyadenylated 
RNA isolated from tumour tissue. The sizes (in base 
pairs) of the principal hybridising RNA species, 
determined by comparison with restriction endonuclease 
Pstl-cut bacteriophage A DNA fragments electro- 
phoresed in parallel, are indicated. 
insert contained in ph8.216 was sequenced: it con- 
sisted of 260 bp including 113 bp of the PPT se- 
quence that had been determined in phE293, 
together with a further 147 bp of 5 ‘-sequence. 
The sequence of 1021 nucleotides of human PPT 
cDNA, determined from clones phE293 and 
ph8.216, is shown in fig.3, together with the 
predicted amino acid sequence of the translated 
product. The human p-PPT polypeptide consists 
of 129 amino acids (Mr 14 820). 
We have established the sequence of a human ,B- 
PPT cDNA cloned from carcinoid tumour tissue. 
The cDNA consists of 81 nucleotides of 
5 ’ -flanking sequence, the complete coding region 
(387 bp) and 533 nucleotides of 3’-untranslated se- 
quence. As we have determined the sequence of a 
total of 1051 nucleotides of PPT cDNA, and Nor- 
thern blot analysis indicated that the mature PPT 
mRNA is 1200 nucleotides long, we consider that 
we have cloned cDNA corresponding to at least 
85% of the complete@-PPT mRNA. As well as the 
mature PPT mRNA at 1200 nucleotides, several 
larger RNA species were detected by Northern blot 
analysis. In bovine brain, SP is derived from two 
closely related PPTs, a and fl [4] which are 
generated from a single PPT gene as a result of 
tissue-specific RNA splicing [ 191. Southern blot 
analysis (J.P., unpublished) indicated that human 
PPTs are also encoded by a single gene. These 
larger mRNA species may therefore correspond to 
intermediates in the RNA processing pathway of /?- 
PPT mRNA. The human PPT cDNA sequence 
described here is closely homologous to the P-form 
of bovine PPT cDNA [4]. Amino acid sequences 
corresponding to SP and NkA (nucleotides 
265-297 and 385-414, respectively) are flanked by 
sequences which are sites of post-translational pro- 
cessing. At the N-terminus, the SP sequence is 
flanked by an arginine residue and the NkA se- 
quence by a pair of basic amino acids (Lys-Arg). 
At the C-terminus, both peptides are flanked by a 
sequence (-Gly-Lys-Arg) from which the C- 
terminal amide groups of SP and NkA are 
generated [20]. 
Using the techniques of Edman sequencing, 
amino acid analysis and fast atom bombardment 
mass spectrometry, Roth et al. [6] have 
demonstrated the presence of both SP and NkA in 
human carcinoid tumour tissue. Our results in- 
dicate that in man, SP and NkA are synthesised 
from a single polypeptide precursor highly homo- 
logous to that found in bovine tissues. Nucleotides 
295-402 of human &PPT cDNA encode a peptide 
with a sequence identical to that of porcine NpK 
[3], which differs at a single position (Leu22 -+ 
Ile) from the corresponding region of bovine fl- 
PPT. These studies establish that human NpK has 
an identical sequence to the porcine peptide [3] as P 
69 
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Human 
1 
Bovine 
Human 
61 
Human 
Bovine 
Bovine 
Human 
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Human 
Bovine 
Bovine 
Human 
181 
Human 
Bovine 
Bovine 
Human 
241 
Human 
Bovine 
Human 
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Human 
Bovine 
Bovine 
Human 
361 
Human 
Bovine 
Human 
421 
Human 
Bovine 
Bovine 
Human 
481 
C C+G AT A ACCG G/r\T AC 
GAGAGTGCGGAGCGACCACGTGCGCTCGGAGGAACCAGAGAAACTCAGCACCCCGCGGGA 
GG ACT G G GA T CA 
CTGTCCGTCGCAAAATCCAACATGAAAATCCTCGTGGCCTTGGCAGTCTTTTTTCTTGTC 
_________+______--_+_________+_________+___---___+_______--+ 
MetLysIleLeuValAlaLeuAlaValPhePheLeuVal 
Val Ile PheIle 
A C C C TC T 
TCCACTCAGCTGTTTGCAGAAGAAATAGGAGCCAATGATGATCTGAATTACTGGTCCGAC 
_________+_________+_________+_________+_-----__-+_________+ 
SerThrGlnLeuPheAlaGluGluIleGlyAlaAsnAspAspLeuAsnTyrTrpSerAsp 
Ser Phe 
C A C 
TGGTACGACAGCGACCAGATCAAGGAGGAACTGCCGGAGCCCTTTGAGCATCTTCTGCAG 
_________+__-______+_________+_________+_________+________-+ 
TrpTyrAspSerAspGlnIleLysGluGluLeuProGluProPheGluHisLeuLeuGln 
Ser Met 
T G 
AGAATCGCCCGGAGACCCAAGCCTCAGCAGTTCTTTGGATTAATGGGCAAACGGGATGCT 
_________+_________+_________+_________+_________+___-___--+ 
ArqIleAlaArqArqProLysProGlnGlnPhePheGlyLeuMetGlyLysArqAspAla 
G C CT 
GATTCCTCAATTGAAAAACAAGTGGCCCTGTTAAAGGCTCTTTATGGACATGGCCAGATC 
_________+_________+_________+_________+_________+~~~~~~~~~+ 
AspSerSerIleGluLysGlnValAlaLeuLeuLy~AlaLeuTyrGlyHisGlyGlnIle 
Leu 
G 
TCTCACAAAAGACATAAAACAGATTCCTTTGTTGGACTAATGGGCAAAAGAGCT~TAAAT 
_________+_________+_________+_________+_~~~~~~__+___~~~~~~+ 
SerHisLysArgHisLysThrAspSerPheValGlyLeuMetGlyLysArgAlaLeuAsn 
TG G A G 
TCTGTGGCTTATGAAAGGAGTGCAATGCAGAATTATGAAAGAAGACGTTAATAAACTACC 
_________+_____-___+_-_______f---___-_____+_________+_________+ 
SerValAlaTyrGluArgSerAlaMetGlnAsnTyrGluArgArgArgEnd 
Val ASP LYS 
A G G T GA AG 
TAACATTATTTATTCAGCTTCATTTGTGTCAATGGGCAATGACAGGTAAATTAAGACATG 
_________ +-_-______+_________+_________+_________+~~~~~~~~~+ 
60 
120 
180 
240 
360 
420 
480 
540 
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Bovine TTG TAT C G 
Human CACTATGAGGAATAATTATTTATTTAATAACAATTGTTTAGGGTTGA-AAATTCAAAAAGT 
541 L---L---- +__~_~_~~~+--__~~~_-+__~~_____+_________+_________+ 
Bovine A 
AAA 
G AG V A G T C C 
Human GTTTATTTTTCATATTGTGCCAATATGTATTGTAAACATGTGTTTTAATTCCAATATGAT 
601 _---_---_ +______---+ ---..----- +_________+_________+______-__+ 
Bovine A Q AGC G C A cc C G 
Human GACTCCCTTAAAATAGAAATAAGTGGTTATTTCTCAACAAAGCACAGTGTTAAATGAAAT 
661 ____~___~+______~~_+~~__~~~_~+__~___~~_+~~_~~____+__~___~__+ 
Bovine TT G A GA TT TC AC GG w T G CA 
Human TGTAAAACCTGTCAATGATACAGTCCCTAAAGAAAAAAAATCATTGCTTTGAAGCAGTTG 
721 _________ +__-______+_________+______-__+-_______-+_~~~~~~~_+ 
Bovine CA AAT GA A T QAT T AG cn 
Human TGTCAGCTACTGCGGAAAAGGAAGGAAACTCCTGACAGTCTTGTGCTTTTCCTATTTGTT 
781 _-______-+__--_____ +~~______~+__~___-~~+~~_~~~_~~+_~~__~~~_+ 
Bovine G A6 C A G c c 
Human TTCATGGTGAAAATGTACTGAGATTTTGGTATTACACTGTATTTGTATCTCTGAAGCATG 
841 ________-+__-______+_________+_________+_________+~~~~~~___+ 
Bovine &A A TC GA 
Human TTTCATGTTTTGTGACTATATAGAGATGTTTTTAAAAGTTTCAATGTGATTCTAATGTCT 
901 ------___+ -_____-__+-________+______-__+_________+______--_+ 
Bovine A T CA A T G 
Human TCATTTCATTGTATGATGTGTTGTGATAGCTAACATTTTAAATAAAAGAAAAAATATCTT 
961 _-_______+______--- +--__--___+______-__+____-____+_________+ 
Bovine A 
Human G 
1021 - 
600 
660 
720 
780 
840 
900 
960 
1020 
Fig.3. The sequence of cDNA for human @PPT and the deduced sequence of the precursor polypeptide. Numbering 
of nucleotides begins with the first nucleotide of cDNA sequence. The sequence of nucleotides l-260 was determined 
from clone ph8.216 and nucleotides 1481021 were sequenced from clone phE293. A sequence of 30 poly(A) residues 
at the end of the sequence of phE293 (immediately 3’ to nucleotide 1021) is not shown. Nucleotides which differ in 
bovine ,&PPT [4] are shown above the main nucleotide sequence: homology between the sequences was maximised by 
inserting gaps [22] indicated by the triangular symbols. Amino acid differences between bovine and human ,&PPT are 
shown below the main polypeptide sequence. 
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suggested by the chromatographic studies of 
Theodorsson-Norheim et al. [7]. 
The protein-coding region of the sequence of 
human ,&PPT mRNA is very similar to that of the 
corresponding legion of bovine ,&-PPT: the 
translation products predicted from the two se- 
quences differ by only 13/130 amino acids (9OVo 
homology) and there is over 92% homology at the 
nucleotide level. Human and bovine fi-PPTs also 
exhibit significant homology in the 5 ’ - and 
3 ’ -untranslated regions (68 and 8 1%) respective- 
ly). The close similarity of the human and bovine 
,&-PPT polypeptides suggests that these precursors 
may give rise not only to SP, NpK and NkA, but 
also to other biologically active peptides. The most 
likely site for the cleavage of the signal sequence 
from human ,&PPT is between Alal and G1uzO 
[21], which would liberate a prohormone of 110 
amino acids (Mr 12868). Post-translational pro- 
cessing of this prohormone could generate two 
novel peptides which may possess biological activi- 
ty: (i) a peptide of approx. 38 amino acids ex- 
tending from the signal peptidase cleavage site to 
the arginine residue immediately N-terminal to the 
SP sequence and (ii) a 19 amino acid peptide, with 
three basic amino acids (Arg-Arg-Arg) at the C- 
terminus, corresponding to nucleotides 412-468 of 
the human p-PPT cDNA sequence. 
Some of the hitherto unexplained clinical 
features of the carcinoid syndrome may be due to 
the secretion of novel peptides derived from ,& 
PPT. The isolation of cDNA clones encoding 
human P-PPT will permit the characterisation of 
these peptides and facilitate studies of the regula- 
tion of PPT gene expression in normal and ectopic 
sites in man. 
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